Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. by Lepore, Angelo C et al.
Human Glial-Restricted Progenitor Transplantation into
Cervical Spinal Cord of the SOD1G93A Mouse Model of
ALS
Angelo C. Lepore1, John O’Donnell2, Andrew S. Kim2, Timothy Williams2, Alicia Tuteja2, Mahendra S.
Rao3,5, Linda L. Kelley4, James T. Campanelli5,6, Nicholas J. Maragakis2*
1Department of Neuroscience, Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States of America, 2Department of Neurology, Johns
Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 3 Life Technologies, Carlsbad, California, United States of America, 4Department of
Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America, 5Q Therapeutics, Salt Lake City, Utah, United States of
America, 6Department of Neurology, University of Utah, Salt Lake City, Utah, United States of America
Abstract
Cellular abnormalities are not limited to motor neurons in amyotrophic lateral sclerosis (ALS). There are numerous
observations of astrocyte dysfunction in both humans with ALS and in SOD1G93A rodents, a widely studied ALS model. The
present study therapeutically targeted astrocyte replacement in this model via transplantation of human Glial-Restricted
Progenitors (hGRPs), lineage-restricted progenitors derived from human fetal neural tissue. Our previous findings
demonstrated that transplantation of rodent-derived GRPs into cervical spinal cord ventral gray matter (in order to target
therapy to diaphragmatic function) resulted in therapeutic efficacy in the SOD1G93A rat. Those findings demonstrated the
feasibility and efficacy of transplantation-based astrocyte replacement for ALS, and also show that targeted multi-segmental
cell delivery to cervical spinal cord is a promising therapeutic strategy, particularly because of its relevance to addressing
respiratory compromise associated with ALS. The present study investigated the safety and in vivo survival, distribution,
differentiation, and potential efficacy of hGRPs in the SOD1G93A mouse. hGRP transplants robustly survived and migrated in
both gray and white matter and differentiated into astrocytes in SOD1G93A mice spinal cord, despite ongoing disease
progression. However, cervical spinal cord transplants did not result in motor neuron protection or any therapeutic benefits
on functional outcome measures. This study provides an in vivo characterization of this glial progenitor cell and provides a
foundation for understanding their capacity for survival, integration within host tissues, differentiation into glial subtypes,
migration, and lack of toxicity or tumor formation.
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Introduction
ALS is a motor neuron disorder characterized by relatively
rapid degeneration of upper and lower motor neurons, with death
from respiratory failure normally occurring 2–5 years following
diagnosis [1]. Approximately 90–95% of ALS cases are sporadic in
nature, with 20% of the remaining familial cases linked to various
point mutations in the Cu/Zn superoxide dismutase 1 (SOD1)
gene [2]. Transgenic mice [3,4,5] and rats [6,7,8] carrying ALS-
associated mutant human SOD1 genes recapitulate many features
of the human disease.
Despite the relative selectivity of motor neuron cell death,
animal and tissue culture models of familial ALS suggest that non-
neuronal cells significantly contribute to neuronal dysfunction and
death [9]. CNS astrocytes outnumber their neuronal counterparts
approximately ten-fold and play key roles in adult CNS
homeostasis, including the vast majority of synaptic glutamate
uptake, maintenance of extracellular potassium and nutrient
support of neurons [10]. Multiple properties of spinal cord and
brain astrocytes are compromised in ALS, and these changes often
precede clinical disease onset [11]. Initial evidence for an astrocyte
contribution to ALS came from studies of humans [12,13] and
rodent ALS models [6] indicating dysfunction and large decreases
in levels of the primary astrocyte glutamate transporter, GLT1
(EAAT2 in human), in areas of motor neuron loss. Confirmation
of a role for non-neuronal cells in modulating mutant SOD1-
induced pathological changes in neighboring motor neurons came
from studies of chimeras of mutant SOD1-expressing cells [14]
and from mice in which mutant SOD1 expression was selectively
reduced in astrocytes [15]. These studies highlight the important
role of astrocyte-motor neuron interactions in the etiology of ALS.
Regardless of whether astrocyte dysfunction is a cause of disease
or a consequence of neuronal death, altered astrocyte physiology
results in further susceptibility to motor neuron loss and
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25968
contributes to disease progression. We previously reported that
targeted enrichment of normal astrocytes in SOD1G93A rat
cervical spinal cord via intraspinal transplantation of rodent-
derived Glial-Restricted Progenitors (GRPs) promoted focal motor
neuron protection, delayed decline in respiratory function and
extension in disease progression [16]. Efficacy was partly mediated
by transplant-based replacement of astrocyte GLT1, presumably
via restoration of extracellular glutamate homeostasis by prevent-
ing ALS-associated loss of GLT1. GRPs were specifically
transplanted around cervical spinal cord respiratory motor neuron
pools (phrenic motor neurons), the principal cells innervating the
diaphragm whose dysfunction precipitates death in ALS patients
[17,18] and animals expressing mutant SOD1 [19,20]. Collec-
tively, these findings indicated the feasibility and efficacy of
transplantation-based astrocyte replacement and showed that
targeted multi-segmental cell delivery to cervical spinal cord is a
promising therapeutic strategy for slowing focal motor neuron loss,
particularly because of its relevance to addressing respiratory
compromise associated with ALS.
The overall goal of the present study was to extend this work to
an analogous class of human GRPs [21,22]. We sought to
demonstrate safety and therapeutic efficacy of transplantation of
hGRPs into the cervical spinal cord ventral horn of the SOD1G93A
mouse model of ALS, as well as to extensively characterize the
long-term in vivo cell fate of hGRPs in the ALS spinal cord.
Materials and Methods
Ethics Statement
Brain tissue from fetal cadavers of gestational age from 17 to 24
weeks is used as the starting material for isolation and purification
procedures of hGRPs. Tissue is procured by Procurement
Specialists employed by Advanced Bioscience Resources (ABR;
Alameda CA; FEIN 3005208435) following Donor ID and
Informed Consent SOPs and Donor Medical Record Review
procedures. ABR has contractual agreements with physicians and
medical facilities or clinics in the United States wherein pregnancy
terminations take place, which allow ABR personnel to be present
in the medical facility at the time of the surgical procedures. When
a patient has decided to proceed with a pregnancy termination,
she signs a clinic-generated informed consent to that effect. After
she has made that decision and signed the surgical consent, the
patient is presented with information regarding the opportunity to
donate fetal tissue and to allow a peripheral blood sample to be
taken from her, for infectious disease testing or to identify specific
markers in the blood. If she desires to participate in donation, she
signs an additional ABR-generated consent for that purpose,
which is presented and witnessed by clinic staff. Clinic staff inform
on-site ABR personnel regarding the patients’ wishes for
participation or declination. If the patient agrees to participate,
ABR personnel wait for the surgical termination to be completed,
and then proceed with tissue identification and procurement. If
suitable fetal or other POC tissue is identified for distribution,
ABR’s certified phlebotomists may then acquire a peripheral blood
sample from the participating patient by performing venipuncture,
or by utilizing the clinic-inserted IV. The historical average is four
tissues per month (over the past two years).
The Johns Hopkins Institutional Review Board has concluded
that studies with surgical materials are exempted from Human
Subjects Approval pursuant to Federal Register 46.101 Exemption
Number 4. Research described will involve the preparation of
surgical samples in which ‘‘information is recorded by the
investigator in such a manner that subjects cannot be identified
directly or through identifiers linked to the subjects’’. The
application (#NA_00021112) was reviewed by JHM IRB. This
obtaining of cells was funded through the Maryland Stem Cell
Research Act of 2006. The IRB determined on August 7, 2008
that the project qualified for an exemption determination under
federal regulations at 45 CFR 46.101(a).
The Johns Hopkins Animal Care and Use Committee (ACUC)
approved the research protocol #MO10M449 for the transplan-
tation studies of these cells on Dec 9, 2010 (expires Dec 9, 2011).
Human Glial-Restricted Progenitors (hGRPs)
Derivation and Selection of Human Glial-Restricted
Progenitors (hGRPs). hGRPs (also referred to as Q-CellsH)
were derived as previously described [21,22]. Briefly, fetal
forebrain (17–24 weeks gestational age) was mechanically and
enzymatically dissociated, followed by positive selection via
magnetic-activated cell sorting with the glial progenitor-specific
cell-surface antigen, A2B5.
Culturing of hGRPs. Following selection, hGRPs were
cultured in vitro on polyornithine-coated flasks [DMEM-F12 with
L-glutamine and 15.0 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (Life Technologies; Carlsbad, CA), 1X N1 (Sigma-
Aldrich; St. Louis, MO), 0.01% human serum albumin (Baxter;
Deerfield, IL), 20.0 ng/mL bFGF (Peprotech; Rocky Hill, NJ),
10.0 ng/mL PDGF-AA (Peprotech)] for 20 days and subsequently
frozen [0.5X medium, 1X ProFreeze non-animal origin freezing
medium (Lonza BioWhittaker; Basel, Switzerland), 7.5% DMSO
(Sigma-Aldrich)]. Frozen aliquots were thawed and immediately
prepared for injections as described below [16].
Cell Transplantation
Experimental Design. Three transplantation experiments
were conducted. In Cohort #1, 50–60 day old SOD1G93A mice
were transplanted with ‘‘low dose’’ of hGRPs (Q-Cells; n = 16
SOD1G93A mice) or human fibroblasts (hFs; ScienCell, Human
Dermal Fibroblasts - fetal; n = 22), and were immunesuppressed
via daily Sub-Q injections of CSA. In Cohort#2, 50–60 day old
SOD1G93A mice again received ‘‘low dose’’ of hGRPs (n = 20) or
hFs (n = 20), but were immunosuppressed via daily I.P. injections
of FK-506 (Tacrolimus)/Rapamycin (Sirolimus). In Cohort #3,
50–60 day old SOD1G93A mice received ‘‘high dose’’ of hGRPs
(n= 11) or hFs (n = 12), and were again immunosuppressed via
daily I.P. injections of FK-506/Rapamycin. Refer to Table 1 for
summary of experimental design.
Preparation of hGRPs for Transplantation. hGRPs and
hFs were suspended (in basal medium) at a concentration of either
2.56104 cells/mL (Experiments 1 and 2) or 7.56104 cells/uL
(Experiment 3). After the completion of the transplantation
session, cell viability was assessed using the trypan blue assay
and was always found to be greater than 75%.
Human GRP Transplantation. Immune suppressed
animals received transplants at 50–60 days of age. Each mouse
received 4 grafts (bilaterally at C4 and C5) of 5.06104 cells/site
(Experiments 1 and 2) or 1.56105 cells/site (Experiment 3) (in
2 mL basal media) into ventral horn. Briefly, cells were delivered
using a 10 mL Hamilton Gastight syringe with an attached 30-
gauge 45u beveled needle (Hamilton; Reno, NV). The injection
pipette was secured to a manual micromanipulator (World
Precision Instruments; Sarasota, FL) attached to an 80u tilting
base [16]. The tip was lowered to a depth of 0.75 mm below the
surface of the cord and was held in place for 2 minutes before and
after cell injection. Cells were delivered under the control of a
microsyringe pump controller (World Precision Instruments) at a
rate of 0.5 mL/minute.
Human Glial Transplantation into ALS Mouse Model
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Immune suppression. Animals were immune suppressed by
subcutaneous administration of cyclosporine A (10 mg/kg; Sandoz
Pharmaceuticals, East Hanover, NJ) or by intraperitoneal admini-
stration of FK-506/Rapamycin (1 mg.kg/each; LC Laboratories;
Woburn, MA) daily beginning three days before grafting and
continuously until sacrifice.
SOD1G93A mice. Transgenic mice carrying the human SOD1
gene with the G93A mutation were used (B6SJL-Tg(SOD1*
G93A)1Gur/J: Stock # 002726) [23,24]. Male and female mice
were obtained from The Jackson Laboratory (Bar Harbor, ME),
and maintained as an in-house colony. On average, untreated
SOD1G93A mutants developed hindlimb disease onset on average at
95–105 days of age, subsequently developed forelimb onset on
average at 110–120 days of age, and reached disease endstage at
approximately 120–125 days of age. For all studies, equal numbers
of males and females were included in all groups, and animals from
the same litter were distributed amongst groups.
Care and Treatment of Animals. All procedures was
conducted in strict accordance with the guidelines set by the
European Communities Counsel Directive (November 24th,
1986), the NIH Guide for the Care and Use of Laboratory
Animals, the Guidelines for the Use of Animals in Neuroscience
Research and the Johns Hopkins University IACUC, and
measures were taken to minimize any potential pain or animal
discomfort. Mice were housed at standard temperature (21uC) and
in a light controlled environment with ad libitum access to the food
and water, and were maintained in racks of ventilated cages
located in the same room. In order to avoid dehydration, Aqua-Jel
Table 1. Summary of Experimental Findings: Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the
SOD1G93A Mouse Model of ALS.
Cohort #1 Cohort #2 Cohort #3
Immune Suppression Cyclosporin A (Sub-Q)
10 mg/kg daily
FK-506/
Rapamycin (I.P.)
1 mg/kg each daily
FK-506/
Rapamycin (I.P.)
1 mg/kg each daily
Cell Dose ‘‘Low Dose’’ Transplantation
50,000 cells/site
4 sites/spinal cord
‘‘Low Dose’’ Transplantation
50,000 cells/site
4 sites/spinal cord
‘‘High Dose’’ Transplantation
150,000 cells/site
4 sites/spinal cord
Age at Txn (Days) 50–60 50–60 50–60 50–60 50–60 50æ60
Cell Type Human Fibroblasts Q Cells Human Fibroblasts Q Cells Human Fibroblasts Q Cells
Survival (Days) 119.0
+/2 1.9
121.0
+/2 2.2
125.4
+/2 2.3
127.9
+/2 1.9
119.0
+/2 1.9
122.5
+/14.1
Hindlimb Onset (Days) 94.5
+/2 2.3
94.4
+/2 3.6
106.8
+/2 1.7
108.6
+/2 2.1
99.4
+/2 14.4
101.2
+/2 13.3
Forelimb Onset (Days) 111.7
+/2 2.4
112.3
+/2 2.8
117.5
+/2 0.1
117.4
+/2 1.7
112.9
+/2 12.9
106.6
+/2 15.7
Duration (Days) 24.5
+/2 2.5
26.3
+/2 3.3
18.1
+/2 2.7
18.8
+/2 1.7
15.3
+/2 3.2
15.0
+/2 2.8
CMAPs (mV) ND ND 4.3
+/2 0.7
4.5
+/2 0.6
2.7
+/2 0.4
3.3
+/2 0.7
Cervical Motor Neurons/
Section
ND ND 5.6
+/2 0.1
6.1
+/2 0.4
2.98
+/2 0.1
2.95
+/2 0.1
n 22 16 20 20 12 11
p.0.05 for all analyses p.0.05 for all analyses p.0.05 for all analyses
doi:10.1371/journal.pone.0025968.t001
Table 2. Antibody Details.
Antibody Target of Recognition Manufacturer Species Dilution
Nestin Undifferentiated Neural Precursor Pharmingen Mouse Monoclonal 1:1,000
A2B5 Glial-Restricted Precursors Millipore Mouse Monoclonal 1:500
bIIITubulin Neurons Covance Rabbit Polyoclonal 1:100
ChAT Motor Neurons Millipore Mouse Monoclonal 1:500
GFAP Astrocytes Dako Rabbit Polyoclonal 1:400
Olig2 Oligodendrocyte Lineage Millipore Rabbit Polyoclonal 1:200
Ki67 Proliferating Cells Lab Vision Rabbit Polyoclonal 1:400
Synapsin Pre-synaptic Terminals BD Bio Rabbit Polyoclonal 1:100
Iba1 Microglia Wako Rabbit Polyoclonal 1:200
GLT1 Astrocyte Glutamate Transporter Rothstein Lab Rabbit Polyoclonal 1:500
doi:10.1371/journal.pone.0025968.t002
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packs were provided when animals started to show disease
symptoms.
Behavioral and Electrophysiological Analyses
Hindlimb and Forelimb Grip Strength. Animal weighing
and all behavioral data collection began 1 week prior to
transplantation, and was conducted twice weekly until end-stage.
Hind- and forelimb muscle grip strengths were separately
determined using a ‘‘Grip Strength Meter’’ (DFIS-2 Series
Digital Force Gauge; Columbus Instruments, OH) [16]. Grip
strength testing was performed by allowing the animals to grasp a
thin bar attached to the force gauge. This was followed by pulling
the animal away from the gauge until the hind- or forelimbs
released the bar. This provides a value for the force of maximal
grip strength. The force measurements were recorded in three
separate trials, and the averages were used in analyses.
Disease Onset. Hind- and forelimb disease onsets were
assessed individually for each mouse by a 20.0% loss in hind- or
forelimb grip strength relative to each animal’s own baseline grip
strength level [16].
Survival/Endstage Analysis. To determine disease
endstage in a reliable and ethical fashion, endstage was defined
by the inability of mice to right themselves within 30 seconds when
placed on their sides.
Disease Duration. Overall onset of disease was determined
by hindlimb grip strength onset because hindlimb deficits were the
first clinical symptoms observed in the vast majority of mice.
Disease duration was measured as time between hindlimb disease
onset and disease endstage [16]. All SOD1G93A animals were
included in overall survival, disease onset and grip strength
analyses; however, mice that displayed forelimb onset prior to
hindlimb onset (approximately 10% of SOD1G93A mice) were
Figure 1. Cohort #1: ‘‘low dose’’ hGRP transplantation in combination with CSA did not promote functional efficacy. Compared to
control transplantation of hFs, ‘‘low dose’’ hGRP transplantation in combination with CSA-based immune suppression neither accelerated nor slowed
progression of disease in SOD1G93A mice. Unchanged outcome measures included weight loss (A), overall survival (B), declines in hindlimb (C) and
forelimb (D) grip strength, hindlimb (E) and forelimb (F) disease onsets, and disease duration (G).
doi:10.1371/journal.pone.0025968.g001
Figure 2. Cohort#2: hGRPs in combination with FK-506/Rapamycin survived and migrated in SOD1G93A cervical spinal cord. Unlike
the lack of hGRP survival observed in SOD1G93A mice with CSA-based immune suppression, HuNA+ hGRP transplant-derived cells survived until
disease endstage (up to 3 months post-transplantation) with FK-506/Rapamycin (A–D). Cells survived in both white and gray matter regions;
however, a larger number of hGRP-derived cells were located in the white matter (C–D). On average, greater than 200,000 total cells survived in each
spinal cord at endstage (C). HuNA+ cells also migrated both rostrally and caudally throughout the gray and white matter of the cervical spinal cord,
up to distances of 0.6 cm from the injection sites; however, the vast majority of cells were located within 2 mm rostral and caudal of the injection
sites (D). Scale bars: 500 mm.
doi:10.1371/journal.pone.0025968.g002
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excluded from disease duration analysis, as well as from analysis of
the delay of forelimb onset following hindlimb onset.
Compound Muscle Action Potential (CMAP)
Recordings. Under anesthesia, phrenic nerve conduction
studies were performed with stimulation (0.5 ms single stimulus;
1 Hz supramaximal pulses) at the neck via near nerve needle
electrodes placed 0.5 cm apart along the phrenic nerve [19,20].
Recording was obtained via a surface strip along the costal margin,
and CMAP amplitude was measured baseline to peak. Recordings
across the nerve segment were made using an ADI Powerlab 8SP
stimulator and BioAMP amplifier (AD Instruments: Colorado
Springs, CO), followed by computer assisted data analysis (Scope
3.5.6; ADI). Distal motor latency of evoked potentials includes
duration of nerve conduction between stimulating and recording
electrodes plus time of synaptic transmission. CMAPs were
collected at only a single time point (120 days of age).
Histological and Biochemical Analyses
Tissue Processing. Animals were sacrificed at 2 and 4 weeks
post-transplantation, at 120 days of age, or at disease endstage by
transcardial perfusion with 0.3% saline, followed by ice-cold 4%
paraformaldehyde (Fisher Scientific; Pittsburgh, PA). Spinal cords
were removed from the animal, followed by cryoprotection in 30%
sucrose (Fisher)/.1 M phosphate buffer at 4uC for 3 days. The tissue
was embedded in OCT (Fisher), fast frozen with dry ice, and stored at
280uC until processed. Spinal cord tissue blocks were cut in the
sagittal or transverse planes at 30 mm thicknesses. Sections were
collected on glass slides and stored at220uC until analyzed. Subsets of
spinal cord slices were collected in PBS for free-floating histochemistry.
Quantification of Transplant Survival and Migration.
HuNA (human nuclear antigen; Millipore; Temecula, CA;
monoclonal; 1:400) was used to selectively identify transplant-
derived human cells (both hGRPs and hFs). Total numbers of
HuNA+/DAPI+ hGRPs (or hFs) were quantified in every 6th
section throughout the extent of transplanted spinal cord at disease
endstage [16]. Cell numbers from all sections were summed and
multiplied by 6 to obtain the total number of surviving cells.
Values were expressed as a percentage of the total number of cells
transplanted. hFs were derived from fetal human dermis. Survival
of hFs following transplantation was also assessed with HuNA.
Differentiation and Proliferation Markers. Nestin
(1:1000; monoclonal; Pharmingen; San Diego, CA) was used to
identify undifferentiated NPCs and GRPs [25]. GRPs were
identified using A2B5 (1:500; Millipore) [26]. Neurons were
identified using bIIITubulin (1:100; polyoclonal; Covance;
Princeton, NJ) [16]. Motor neurons were identified with ChAT
(1:500; monoclonal; Millipore). Astrocytes were identified using
pan-GFAP (1:400; polyclonal; Dako; Glostrup, Denmark) or
human-specific GFAP (1:5,000; monoclonal; Dako) [23]. Cells of
the oligodendrocyte lineage were identified using Olig2 (1:200;
polyclonal; Millipore) [27]. Proliferating cells were identified with
Ki67 (1:400; monoclonal; Lab Vision Corp; Fremont, CA) [25].
Pre-synaptic terminals were identified with synapsin (1:100;
polyclonal; BD Biosciences; Sparks, MD). Microglial cells were
detected via Iba1 (1:200; polyclonal; Wako; Richmond, VA) [16].
GLT1 expression by hGRPs was assessed via immunohis-
tochemistry with GLT1 antibody (carboxyl terminus-directed
antibody; 1:500; polyclonal) (Table 2) [6]. Samples were
incubated for 2 hours at room temperature with goat anti-mouse
and goat anti-rabbit secondary antibodies (1:200; Jackson
ImmunoResearch; West Grove, PA) conjugated to rhodamine or
FITC. Samples were counterstained with DAPI (1:1000; Sigma-
Aldrich) to identify nuclei, and cover-slipped with anti-fade
mounting media (Fluorosave, CN Biosciences; La Jolla, CA).
Slides were subsequently stored at 4uC. Images were acquired on
either a Zeiss fluorescence microscope using a Photometric Sensys
KAF-1400 CCD camera (Roper Scientific; Trenton, NJ) or on a
Zeiss laser confocal microscope. Images were analyzed using either
Metamorph or Zeiss confocal software. Adobe Photoshop 7.0
(Adobe; San Jose, CA) was used to prepare figures.
Quantification of Transplant Differentiation and
Proliferation. The proportions of transplant-derived neurons
(NeuN), astrocytes (pan-GFAP), cells of the oligodendrocyte
lineage (Olig2), microglia (Iba1) and actively proliferating cells
(Ki67) were expressed as a percentage of the total number of
transplanted cells counted at specific locations along the cervical
spinal cord relative to sites of injection [16]. In order to quantify
double-labeling of HuNA with lineage-specific (pan-GFAP, Olig2,
NeuN, Iba1) and proliferation (Ki67) markers, double-labeled
sagittal sections containing the entire cervical enlargement, as well
as additional rostral and caudal spinal cord tissue, were imaged at
206magnification using Zeiss AxioVision software. Images were
analyzed in AxioVision at specific distances from the injection
sites. For each animal (n = 6 mice), 6 different 206 images were
analyzed at each specific distance (3 in gray matter, 3 in white
matter. In each image, every HuNA+ cell with a matching DAPI+
Figure 3. Cohort #2: hGRPs with FK-506/Rapamycin occupied a significant portion of the cervical spinal cord in SOD1G93A mice.
Human GRP transplant-derived cells (from 4 injection sites: bilaterally at C4 and C5) dispersed to occupy a significant portion of the cervical spinal
cord, as demonstrated by the sagittal series of HuNA-stained sections from a single animal (slices are approximately 200 mm apart). Scale bar: 500 mm.
doi:10.1371/journal.pone.0025968.g003
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nucleus was assessed for co-expression of the lineage-specific
marker, and these data were pooled from the 3 images to
determine the value at each distance for each animal.
Motor Neuron Survival. The cervical (C4–C6) spinal cord
was serially sectioned transversely (30 mm) and stained with cresyl
violet (Sigma-Aldrich) to quantify motor neuron numbers. Motor
neurons were counted in every 7th section at 206magnification in
order to avoid repetitive counting. Only motor neurons with a
clearly identifiable nucleus and nucleolus, a cell soma over
100 mm2 and located within the ventral horn were counted at a
200-fold magnification, and the final counts were multiplied by
seven to give an estimate of total cell numbers [16].
Western Analysis. Aliquots of homogenized cord samples
from C5 were separately subjected to SDS-polyacrylamide gel
electrophoresis. Blots were probed with antibody specific for GLT-
1 (1:5,000) [16]. Immunoreactivity was visualized by enhanced
chemiluminescence, quantified densitometrically using Quantity
One v4.0 software (BioRad; Hercules, CA), and normalized to
actin.
Statistical Analyses
Kaplan-Meier analysis of the SOD1G93A mice was conducted
using the statistical software Sigmastat (SAS Software) to analyze
survival, disease onset and duration data. Weight and grip strength
results were analyzed via ANOVA. In some cases, Student t-test
was performed to compare data between groups of animals. All
data are presented as mean 6 S.E.M., and significance level was
set at p#0.05.
Figure 4. Cohort#2: hGRPs with FK-506/Rapamycin continued to proliferate in SOD1G93A cervical spinal cord. Approximately 10% of
transplant-derived HuNA+ cells continued to divide at disease endstage, as determined by co-expression of the proliferation marker, Ki67 (A–B). No
differences were noted between gray and white matter (C–D), and the percentage of proliferating cells slightly increased with distance from injection
sites (E). Scale bars: 25 mm.
doi:10.1371/journal.pone.0025968.g004
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Results
Human cells were transplanted into the cervical spinal cord of
SOD1G93A mice. Three separate transplantation experiments
were conducted. In Cohort #1, 50–60 day old SOD1G93A mice
were transplanted with ‘‘low dose’’ of hGRPs (5.06104 cells/site; 4
sites) (n = 16) or unmodified human fibroblasts (hFs; n = 22), and
were immune suppressed via daily subcutaneous injections of
CSA. In Cohort #2, 50–60 day old SOD1G93A mice again
received ‘‘low dose’’ of hGRPs (5.06104 cells/site; 4 sites) (n = 20)
or hFs (n = 20 mice), but were immune suppressed via daily I.P.
injections of FK-506 (Tacrolimus)/Rapamycin. In Cohort #3,
50–60 day old SOD1G93A mice received ‘‘high dose’’ of hGRPs
(1.56105 cells/site; 4 sites) (n = 11) or hFs (n = 12), and were again
Figure 5. Cohort#2: hGRPs with FK-506/Rapamycin did not differentiate into neurons in SOD1G93A cervical spinal cord. HuNA+ hGRP
transplant-derived cells did not differentiate into bIII-Tubulin+ neurons (A–B). At disease endstage, less than 1% of all HuNA+ cells co-expressed bIII-
Tubulin (F). HuNA+ cells spatially interacted with ChAT+ motor neurons (C–D) and synapsin+ pre-synaptic sites (E) within the spinal cord of SOD1G93A
mice. Scale bars: A–B, E 50 mm; C-D 25 mm.
doi:10.1371/journal.pone.0025968.g005
Human Glial Transplantation into ALS Mouse Model
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immune suppressed via daily I.P. injections of FK-506/Rapamy-
cin. Refer to Table 1 for summary of experimental design.
Cohort #1: Human GRPs showed poor survival with
cyclosporine immunosuppression
Compared to control transplantation of hFs, ‘‘low dose’’ hGRP
transplantation in combination with CSA-based immune suppres-
sion neither accelerated nor slowed progression of disease in
SOD1G93A mice (see Table 1 and Figure 1 for summary of
findings). Unchanged outcome measures included weight loss
(Fig. 1A), overall survival (Fig. 1B), declines in hindlimb (Fig. 1C)
and forelimb (Fig. 1D) grip strength, hindlimb (Fig. 1E) and
forelimb (Fig. 1F) disease onsets, and disease duration (Fig. 1G).
This study demonstrates the feasibility and safety of a cervical
cellular transplantation approach in this mouse model of ALS.
Human GRP transplants did not survive at disease endstage in
SOD1G93A mice with CSA-based immune suppression at 10 mg/
kg administered I.P. (data not shown). Because of the effectiveness
of an alternative immune suppression regimen, the combination of
FK-506 and Rapamycin, in supporting hGRP transplant survival
in SOD1G93A mouse spinal cord (pilot study data not shown), FK-
506/Rapamycin was used in subsequent studies to examine
therapeutic efficacy and in vivo transplant fate of hGRPs.
Figure 6. Cohort #2: hGRPs with FK-506/Rapamycin differentiated into astrocytes in SOD1G93A cervical spinal cord. Transplanted
HuNA+ hGRPs differentiated into GFAP+ astrocytes by disease endstage in gray matter both near the injection site (A) and at distances up to 6 mm
(B: image represents region with migrating cells approximately 3 mm caudal to the injection site), as well as in white matter (C). At disease endstage,
approximately 50–80% of all HuNA+ cells co-expressed the astrocyte marker GFAP at sites within 1 mm rostral or caudal of the injection sites,
regardless of whether cells were found in gray (A) or white (C) matter (D). This percentage decreased at greater distances from the injection sites (B,
D). In addition to the pan-GFAP marker, transplanted-derived astrocytes were labeled with the human-specific GFAP marker (E–F). Only a minor
fraction (approximately 1%) of HuNA+ cells co-expressed the microglial marker, Iba1 (G–H). Arrowheads denote HuNA/GFAP double-labeled cells in
panels A and C. Scale bars: 50 mm.
doi:10.1371/journal.pone.0025968.g006
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Cohort #2: Human GRP characterization with FK-506 and
Rapamycin immunosuppression
Cell Survival and Migration. Unlike the lack of hGRP
survival observed in SOD1G93A mice with CSA-based immune
suppression, HuNA+ hGRP transplant-derived cells survived until
disease endstage (up to 3 months post-transplantation) with FK-
506/Rapamycin (Fig. 2A–D). Cells survived in both white and
gray matter regions; however, a larger number of hGRP-derived
cells were located in the white matter (Fig. 2C–D). On average,
greater than 200,000 total cells survived in each spinal cord at
endstage, slightly more than the total number of cells injected at all
four sites combined (Fig. 2C). HuNA+ cells also migrated both
rostrally and caudally throughout the gray and white matter of the
cervical spinal cord, up to distances of 6.0 mm from the injection
sites; however, the vast majority of cells were located within 2 mm
rostral and caudal of the injection sites (Fig. 2D). Human GRP
transplant-derived cells (from 4 injection sites: bilaterally at C4 and
C5) dispersed to occupy a significant portion of the cervical spinal
cord, as demonstrated by the sagittal series of HuNA-stained
sections from a single animal shown in Figure 3 (slices are
approximately 200 mm apart). Unlike hGRPs, very low survival of
hFs was observed at disease endstage (data not shown), which may
be due to the ectopic nature of a human dermal fibroblast
transplant into host rodent neural tissue.
Proliferation. Approximately 10% of transplant-derived
HuNA+ cells continued to divide at disease endstage, as
determined by co-expression of the proliferation marker, Ki67
(Fig. 4A–B). No differences were noted between gray and white
matter (Fig. 4C–D), and the percentage of proliferating cells
slightly increased with distance from injection sites (Fig. 4E),
suggesting that a larger proportion of migrating cells remained in
an undifferentiated state compared to cells closer to the injection
sites. While the proportion of cells that continued to divide
remained small, these data suggest that a small amount of
continued proliferation over several months likely contributed to
the impressive degree of cell survival observed (i.e. numbers of cells
equal to or greater than originally transplanted).
Neuronal Differentiation. HuNA+ hGRP transplant-
derived cells did not differentiate into bIII-Tubulin+ neurons
(Fig. 5A–B). At disease endstage, less than 1% of all HuNA+ cells
co-expressed bIII-Tubulin (Fig. 5F). HuNA+ cells spatially
interacted with ChAT+ motor neurons (Fig. 5C–D) and
synapsin+ pre-synaptic sites (Fig. 5E) within the spinal cord of
SOD1G93A mice.
Astrocyte Differentiation. Transplanted HuNA+ hGRPs
differentiated into GFAP+ astrocytes by disease endstage in gray
matter both near the injection site (Fig. 6A) and at distances up to
6 mm (Fig. 6B: image represents region with migrating cells
Figure 7. Cohort #2: hGRPs did not express the astrocyte glutamate transporter GLT1 in SOD1G93A cervical spinal cord.
Immunohistochemical analysis human GRP transplant-derived cells does not reveal expression of the astrocyte glutamate transporter, GLT1, in the
SOD1G93A spinal cord at disease endstage (A–C). Intraspinal levels of GLT1 were measured using Western blotting of whole cervical spinal cord
segments at C5. hGRPs did not slow the loss of intraspinal GLT1 protein levels compared to hF controls (D). Asterisks denote regions with large
numbers of transplant-derived cells, but no GLT1 expression. Scale bars: 200 mm.
doi:10.1371/journal.pone.0025968.g007
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approximately 3 mm caudal to the injection site), as well as in
white matter (Fig. 6C). At disease endstage, approximately 50–
80% of all HuNA+ cells co-expressed the astrocyte marker GFAP
at sites within 1 mm rostral or caudal of the injection sites,
regardless of whether cells were found in gray or white matter
(Fig. 6D). This percentage decreased at greater distances from the
injection sites. Across the entire spinal cord, 57.1 +/2 0.02% of all
HuNA+ cells differentiated into GFAP astrocytes, with little
difference between gray and white matter regions (gray matter:
58.8 +/2 0.02%; white matter: 56.1 +/2 0.10%). Only 25–40%
of HuNA+ hGRP transplant-derived cells differentiated into
GFAP+ astrocytes when analyzed at 3 weeks post-transplantation
(not shown). In addition to the pan-GFAP marker, transplanted-
derived astrocytes were labeled with the human-specific GFAP
marker (Fig. 6E–F). Only a minor fraction (approximately 1%) of
HuNA+ cells co-expressed the microglial marker, Iba1 (Fig. 6G–
H).
Human GRP transplant-derived cells did not appear to express
the major astrocyte glutamate transporter, GLT1, in the
SOD1G93A spinal cord at disease endstage (Fig. 7A–C).
Intraspinal levels of GLT1 were measured using Western blotting
of whole cervical spinal cord segments at C5. Human GRPs did
not slow the loss of intraspinal GLT1 protein levels compared to
hF controls (Fig. 7D).
Oligodendrocyte Lineage Differentiation. At disease
endstage, HuNA+ cells co-labeled with the oligodendrocyte
lineage marker, Olig2 (Fig. 8A–B). However, it is possible that
Olig2 also marks glial precursor cells destined to differentiate into
astrocytes [27]. Close to the injection sites, approximately 10–30%
of the HuNA+ cells expressed Olig2, in both gray and white matter
regions (Fig. 8C). This percentage was higher at greater distances
from the injection sites, which taken together with the inverse
correlation of GFAP expression percentage with distance (Fig. 6B),
may suggest that a GRP progeny biased to become an
oligodendrocyte (OPC) has greater migratory ability than a GRP
progeny biased to become an astrocyte (APC).
Lack of Phenotypic Efficacy. Despite robust survival and
the significant differentiation of hGRPs into astrocytes throughout
the cervical spinal cord of SOD1G93A mice, ‘‘low dose’’ hGRP
transplantation in combination with FK-506 and Rapamycin-
based immune suppression neither accelerated nor slowed
progression of disease in SOD1G93A mice (see Table 1 and
Figure 9 for summary of findings) when compared to control
transplantation of hFs. Unchanged outcome measures included
weight loss (Fig. 9A), overall survival (Fig. 9B), declines in
hindlimb (Fig. 9C) and forelimb (Fig. 9D) grip strength, hindlimb
(Fig. 9E) and forelimb (Fig. 9F) disease onsets, and disease
duration (Fig. 9G). Taken together with the robust hGRP survival
and distribution documented above, these findings further
document the safety of the surgical transplantation approach, as
well as the safety of persistent hGRP grafts in vivo.
Lack of Neuroprotection. To evaluate the ability of hGRPs
to preserve respiratory function in SOD1G93A animals, mice
receiving hGRP (n= 5) or hF (n= 6) transplants were tested at
Figure 8. Cohort #2: hGRPs with FK-506/Rapamycin differentiated towards the oligodendrocyte lineage in SOD1G93A cervical
spinal cord. At disease endstage, HuNA+ cells co-labeled with the oligodendrocyte lineage marker, Olig2 (A–B). Close to the injection sites,
approximately 10–30% of the HuNA+ cells expressed Olig2, in both gray and white matter regions (C). This percentage was higher at greater
distances from the injection sites. Scale bars: 50 mm.
doi:10.1371/journal.pone.0025968.g008
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120 days of age (+/2 3 days) for peak compound muscle action
potentials (CMAP) amplitudes (Fig. 10A) in one hemi-diaphragm
following ipsilateral phrenic nerve stimulation, an electrophysio-
logical assay of respiratory function [19,20]. Pre-symptomatic
SOD1G93A mice had peak CMAP amplitudes of 7.0–8.0mV (not
shown). All SOD1G93A animals had significantly reduced CMAP
amplitudes at 120 days of age, demonstrating that SOD1G93A-
mediated disease results in compromised respiratory function;
however, there was no significant difference between experimental
groups (Fig. 10B).
This lack of efficacy as assessed by behavioral and respiratory
functional outcome measures was paralleled by a lack of
neuroprotection of cervical spinal cord motor neurons. Cervical
motor neurons were counted throughout the cervical enlargement
in cresyl violet stained sections (Fig. 10C). There was no difference
in cervical motor neuron survival between mice receiving hGRP
and hF transplants at disease endstage (Fig. 10D; n = 4/group).
Cohort #3: High Dose Human GRPs Transplantation with
FK-506 and Rapamycin Immunosuppression
Cell Survival and Migration. Similar to ‘‘low dose’’
transplantation with FK-506/Rapamycin, hGRP transplants
robustly survived until disease endstage. The patterns of survival,
localization and migration (Fig. 11B), as well as differentiation
(data not shown), were similar to those documented for ‘‘low dose’’
transplant fate. As expected, greater cell numbers were found at
endstage with the ‘‘high dose’’ transplants (Fig. 11A).
Interestingly, the bias seen in Cohort 2 (low dose) toward white
matter residence of graft progeny (Fig. 2C–D) was reversed in the
high dose cohort (Fig. 11A–B). It is worth noting that the absolute
number of hGRP progeny present in white matter at both doses
was comparable, possibly suggesting a saturation point for
exogenously grafted cells in the white matter microenvironment.
Lack of Phenotypic Efficacy. Given the lack of efficacy
observed with hGRP cell transplantation despite survival and
Figure 9. Cohort #2: ‘‘low dose’’ hGRP transplantation with FK-506/Rapamycin did not promote functional efficacy. Compared to
control transplantation of hFs, ‘‘low dose’’ hGRP transplantation in combination with FK-5-6/Rapamycin-based immune suppression neither
accelerated nor slowed progression of disease in SOD1G93A mice. Unchanged outcome measures included weight loss (A), overall survival (B),
declines in hindlimb (C) and forelimb (D) grip strength, hindlimb (E) and forelimb (F) disease onsets, and disease duration (G).
doi:10.1371/journal.pone.0025968.g009
Figure 10. Cohort #2: ‘‘low dose’’ hGRP transplantation with FK-506/Rapamycin did not protect respiratory function or cervical
motor neurons. All SOD1G93A animals had significantly reduced phrenic CMAP amplitudes at 120 days of age (A), demonstrating that SOD1G93A-
mediated disease results in compromised respiratory function; however, there was no significant difference between hGRP and hF groups (B).
Cervical motor neurons (denoted by arrowheads) were counted throughout the cervical enlargement in cresyl violet stained sections (C). There was
no difference in cervical motor neuron survival between mice receiving hGRP and hF transplants at disease endstage (D). Scale bars: 50 mm.
doi:10.1371/journal.pone.0025968.g010
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astrocyte differentiation, we evaluated the therapeutic efficacy of
an increased ‘‘dose’’ of transplanted hGRPs, three times the cell
number used in Cohort 1 and 2. Cells were delivered using the
exact same protocol as described above.
Compared to control ‘‘high dose’’ transplantation of hFs, ‘‘high
dose’’ hGRP transplants in combination with FK-506 and
Rapamycin-based immune suppression neither accelerated nor
slowed progression of disease in SOD1G93A mice (see Table 1 and
Figure 12 for summary of findings). Unchanged outcome
measures included weight loss (Fig. 12A), overall survival
(Fig. 12B), declines in hindlimb (Fig. 12C) and forelimb
(Fig. 12D) grip strength, hindlimb (Fig. 12E) and forelimb
(Fig. 12F) disease onsets, and disease duration (Fig. 12G).
Lack of Neuroprotection. All SOD1G93A animals had
significantly reduced CMAP amplitudes at 130 days of age;
however, there was no significant difference between experimental
groups (Fig. 11C; n = 5/group). There was also no difference in
cervical motor neuron survival between mice receiving hGRP and
hF transplants at disease endstage (Fig. 11D; n = 5/group).
Discussion
One of the greatest challenges in potentially using cell
replacement therapy for ALS is the progressive nature of the
disease. This progression has made the concept of using motor
neuron progenitors for reinervation and regeneration a limiting
factor. Current technologies do not currently exist to magnify axon
outgrowth to outpace a neurodegenerative disease where survival
is 2–5 years following a diagnosis [28]. With this in mind, cell
therapeutic strategies have turned to non-neuronal cells (including
astrocytes, but also myocytes, oligodendrocytes, microglia, and
mesenchymal stem cells, amongst others) for their potential in
providing motor neuron protection and slowing disease progres-
sion.
We have previously reported that wild-type rodent-derived
GRPs (rGRPs) transplanted into the cervical spinal cords of
SOD1G93A rats differentiated into astrocytes and provided
neuroprotection resulting in phenotypic improvement in these
ALS animals [16]. The present study investigated the safety and in
vivo survival, distribution, differentiation, and potential efficacy of
clinically relevant analogous human Glial-Restricted Progenitors
(hGRPs) [21,22]. We report that hGRP transplants survived and
distributed throughout much of the cervical spinal cord of
SOD1G9A3 mice and differentiated into astrocytes, but did not
provide a phenotypic sparing of function.
At disease endstage, approximately 50–80% of hGRPs
differentiated into astrocytes close to the injection sites, while this
percentage sharply dropped with increasing distances. We
observed differentiation of hGRPs into cells of the oligodendrocyte
lineage as well. These data suggest that while the majority of
hGRPs differentiate into astrocytes in this in vivo paradigm, these
cells continue to maintain their capacity for differentiation into
Figure 11. Cohort #3: ‘‘high dose’’ hGRP transplantation with FK-506/Rapamycin did not protect respiratory function or cervical
motor neurons. Greater cell survival was found with the ‘‘high dose’’ transplants compared to ‘‘low dose’’ transplants, with a greater proportion of
cells localizing to gray matter than white matter (A). Transplant-derived cells migrated from injection sites up to distances of 6 mm (B). All SOD1G93A
animals had significantly reduced phrenic CMAP amplitudes at 130 days of age, however, there was no significant difference between hGRP and hF
groups (C). There was no difference in cervical motor neuron survival between mice receiving hGRP and hF transplants at disease endstage (D).
doi:10.1371/journal.pone.0025968.g011
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Figure 12. Cohort#3: ‘‘high dose’’ hGRP transplantation with FK-506/Rapamycin did not promote functional efficacy. Compared to
control ‘‘high dose’’ transplantation of hFs, ‘‘high dose’’ hGRP transplants in combination with FK-506 and Rapamycin-based immune suppression
neither accelerated nor slowed progression of disease in SOD1G93A mice. Unchanged outcome measures included weight loss (A), overall survival (B),
declines in hindlimb (C) and forelimb (D) grip strength, hindlimb (E) and forelimb (F) disease onsets, and disease duration (G).
doi:10.1371/journal.pone.0025968.g012
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other glial phenotypes, as has been described previously [29].
Interestingly, Walczak and colleagues showed that hGRP
transplantation into an inflammatory demyelinated adult rodent
spinal cord also showed significant differentiation of hGRPs into
GFAP+ astrocytes, with only minimal oligodendrocyte differenti-
ation [30]. Whether the propensity of hGRPs to differentiate
primarily into astrocytes reflects the immunosuppression regimen
chosen (both the current study and Walczak et al. used FK-506
and Rapamycin), the nature of the lesion, the proximity of the cells
to the transplant site, or the natural propensity of these cells to
differentiate into GFAP+ astrocytes requires further investigation.
Human GRP-derived cells also continued to proliferate when
assessed at endstage. While 10% of hGRP-derived cells continued
to proliferate, instances of tumor formation were never found at
endstage (up to 3 months post-transplantation). Gross pathological
examination of other organs outside the CNS did not demonstrate
heterotopic engraftment. The absence of either tumor formation
within the CNS or heterotopic engraftment in tissues outside the
CNS is important in establishing the safety of such cells with
regard to their translational capacity for ALS treatment.
Our data suggest that survival of transplanted cells critically
depends on the successful implementation of the appropriate
immune suppression regimen. hGRPs showed poor long-term
survival using the calcineurin inhibitor, cyclosporine A. This
necessitated the combination of FK-506 (tacrolimus) and Rapa-
mycin (sirolimus), a regimen that targets calcineurin- or mTOR-
dependent inhibition of T cell activation, respectively [31] (these
non-specific immune suppression compounds likely exert effects on
other pathways as well). Autologous derivation of cells for
transplantation via patient-specific technologies such as induced
Pluripotent Stem (iPS) cells [32] may eventually obviate the need
for chronic immune suppression of transplant recipients in a
clinical setting, but emerging data also suggest that iPS cells may
also have immunogenic potential [33]. Therefore, the study of cell-
based therapy for transplantation may require parallel analyses of
varying immunosuppression regimens in order to determine the
most efficacious options for cell survival.
A number of differences in the experimental paradigms between
the present work and our previous study utilizing rGRPs
transplanted into SOD1 animal models has made direct
comparisons with the potential utility of hGRPs in managing
ALS limited. These include, first and foremost, the use of a
shorter-lived SOD1G93A mouse in the current study, as compared
with the longer-living SOD1G93A rat model that we previously
used. Other differences include the immunosuppression regimen,
number of injection sites in the spinal cord (4 in the SOD1G93A
mouse and 6 in the previous SOD1G93A rat study: due to
significant species spinal cord size differences), and fewer numbers
of transplanted cells used in the current study (66105 total cells in
current study’s ‘‘high-dose’’ group compared to 96105 in the
previous SOD1G93A rat study). A number of studies have shown
that analogous rodent and human stem/progenitor cells differ in a
variety of properties, including culturing conditions, gene and
protein expression, proliferation rate and propensity to differen-
tiate into various mature lineages [34,35]. These differences may
account for the lack of efficacy reported in this study, arising for
example from functional differences in the way that xenografted
cells alter host physiology relative to allografts or closely related
(rat/mouse) grafts due to inter-species incompatibility.
Previous studies have transplanted human neural stem cells,
some genetically modified to release GDNF, into the spinal cords
of SOD1G93A rats. Following transplantation, those neural stem
cells releasing GDNF were able to protect motor neurons in
regions where transplanted cells integrated near host motor
neurons. Similar to our current observations, those neural stem
cells also retained immature cellular markers at sites distant from
transplantation and did not have any therapeutic benefit -
presumably because of continued distal denervation at the
neuromuscular junction [36]. Other studies using human neural
progenitor cells expressing GDNF or IGF-1 in the mouse SOD1
model also showed neuroprotection, but no effect on survival [37].
The present study was conducted to extensively characterize the
in vivo fate of human GRPs derived from the human fetal CNS and
to evaluate the therapeutic efficacy of a clinically-relevant neural
precursor cell type in an animal model of ALS. This approach
targets therapy to diaphragmatic function, and is therefore an
important strategy given the central role played by respiratory
dysfunction in the ultimate death of patients [17,18]. While there
are numerous classes of undifferentiated neural precursors [38], as
well as growing interest in clinically-relevant technologies such as
iPS cells [32], we have shown that transplantation of lineage-
restricted progenitors provides a valuable tool for achieving robust
survival and integration, as well as targeted and efficient
differentiation into specific glial phenotypes in vivo.
Future studies with an eye towards clinical translation of this
approach may include an increase in the number of cells
transplanted in order to calculate both a ‘‘dose’’ of cells for
efficacy and also to establish a maximum tolerated ‘‘dose’’ of cells
before toxicity becomes a limiting factor. Increasing the number of
transplant sites for achieving delivery of cells to additional regions
of the spinal cord may also result in improved efficacy [39]. In vitro
manipulations prior to transplantation to increase the yield of
hGRP-derived astrocytes may result in improved host motor
neuron survival. Because this approach is aimed at neuroprotec-
tion rather than neuronal replacement, reconstitution of spinal
cord astrocytes, once optimized, may be a valuable approach to
cellular-based therapeutics.
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